COOL COOL
Theres a critical need for novel therapeutics amid continental epidemics of opioid abuse and suicide.
“Psychedelics as the hottest new therapeutics since Prozac”. - NEW YORK TIMES
Theres also a desperate need for novel medication for dementia and Alzeihmer’s.
A whole body of research suggests psychedelics can enhance learning and memory and possess anti inflammatory effects .
Scientists and entrepreneurs share excitement in the psychedelic revolution. We could see FDA approval of psychoactive compounds in therapy as soon as 2023 for MDMA and psilocybin 1-2 years after that.
Core One Lab’s has not identified any competitors that are currently developing biosynthesized psilocybin.
$COOL is producing pure psilocybin at one hundredth of the standard cost
Speaking about other companies in the psilocybin space, leading microbiologist and &COOL Exec. Chairman, Dr. Robert E. W. Hancock stated:
“You might consider them competitors, but in our case, we consider them to be potential clients.”
$COOL up 1.6% today at $0.62 , mc $44 M